Similar studies for GEO DataSets (Select 5826) - GEO DataSets

Links from GEO DataSets

Items: 20

Select item 58261.

Multiple myeloma cell lines with acquired resistance to chemotherapeutic agent carfilzomib

Analysis of proteasome inhibitor carfilzomib-resistant multiple myeloma (MM) cell lines KMS-11/Cfz and KMS-34/Cfz, after 1 week of growth in the absence of carfilzomib. Results provide insight into the molecular mechanisms underlying the acquisition of proteasome inhibitor resistance in MM.

Organism:: Homo sapiens

Type:: Expression profiling by array, transformed count, 4 cell line, 2 cell type sets

Platform:: GPL570
Series:: GSE69078
12 Samples

Download data: CEL

DataSet

Accession:: GDS5826

ID:: 5826

PubMed Full text in PMC Similar studies GEO Profiles Analyze DataSet

Select item 2000690782.

Comparison of the gene expression profiles of carfilzomib-resistant derivatives versus parental human myeloma cell lines

(Submitter supplied) KMS-11 and KMS-34 cells were exposed to stepwise increasing concentrations of carfilzomib over a period of 18 weeks: cells adapted to growth in 4 nM carfilzomib by 4 weeks, in 6 nM in another 6 weeks and in 12 nM after a further 8 weeks. The resulting cell cultures, denoted KMS-11/Cfz and KMS-34/Cfz, respectively, retained resistance to carfilzomib even when tested after removal of selective pressure for approximately 8 weeks.

Organism:: Homo sapiens

Type:: Expression profiling by array

Dataset:: GDS5826
Platform:: GPL570
12 Samples

Download data: CEL

Series

Accession:: GSE69078

ID:: 200069078

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000780693.

Comparative expression analysis of carfilzomib-resistant and parental LP-1 human multiple myeloma cells

(Submitter supplied) LP-1 cells were exposed to stepwise increasing concentrations of carfilzomib over a period of 18 weeks: cells adapted to growth in 4 nM carfilzomib by 4 weeks, in 6 nM in another 6 weeks and in 12 nM after a further 8 weeks. The resulting cell culture, denoted LP-1/Cfz, retained resistance to carfilzomib even when tested after removal of selective pressure for approximately 8 weeks.

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL570
6 Samples

Download data: CEL

Series

Accession:: GSE78069

ID:: 200078069

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2001568724.

Targeting steroid receptor co-activator 3 sensitizes myeloma cell to proteasome inhibitor treatment through NSD2-mediated phase separation and chromatin remodeling

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing

Platforms:: GPL20795 GPL23227
14 Samples

Download data: BW, NARROWPEAK

Series

Accession:: GSE156872

ID:: 200156872

PubMed Full text in PMC Similar studies

Select item 2001568715.

Targeting steroid receptor co-activator 3 sensitizes myeloma cell to proteasome inhibitor treatment through NSD2-mediated phase separation and chromatin remodeling [RNA-Seq]

(Submitter supplied) Functional crosstalk between histone modifications and chromatin remodeling has emerged as a key regulatory mode of transcriptional control during cell fate decisions, but the underlying mechanisms are not fully understood. Here we demonstrate that some drug resistant genes were activated during myeloma resistant to bortezomib. Mechanistically, NSD2 can interact with SRC-3, its SET domain is responsible to H3K36me2 to enhance the transcriptional activity of SRC-3 target gene. more...

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL23227
8 Samples

Download data: TXT

Series

Accession:: GSE156871

ID:: 200156871

PubMed Full text in PMC Similar studies Analyze with GEO2R SRA Run Selector

Select item 2001568706.

Targeting steroid receptor co-activator 3 sensitizes myeloma cell to proteasome inhibitor treatment through NSD2-mediated phase separation and chromatin remodeling [ChIP-Seq]

(Submitter supplied) Functional crosstalk between histone modifications and chromatin remodeling has emerged as a key regulatory mode of transcriptional control during cell fate decisions, but the underlying mechanisms are not fully understood. Here we demonstrate that NSD2/SRC-3 complex coordinates histone H3 lysine 36 dimethylation (H3K36me2) and transcriptional elongation factor Pol II to regulate chromatin dynamic and gene transcription during myeloma resistant to bortezomib. more...

Organism:: Homo sapiens

Type:: Genome binding/occupancy profiling by high throughput sequencing

Platform:: GPL20795
6 Samples

Download data: BW, NARROWPEAK

Series

Accession:: GSE156870

ID:: 200156870

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 2001408607.

NSD2 interacts with SMARCA2 and regulates expression of oncogenes CCND1 and PRL3 in t(4;14) multiple myeloma

(Submitter supplied) Recurrent chromosomal translocations are central to the pathogenesis of multiple myeloma (MM), with t(4;14) translocation being the second-most common and associated with poor prognosis. The nuclear receptor-binding SET domain 2 (NSD2) is overexpressed as a result of the translocation and has been suggested to be the primary oncogenic factor in t(4;14) MM. However, the detailed oncogenic mechanism of NSD2 in MM is still not completely understood. more...

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL16791
4 Samples

Download data: TXT

Series

Accession:: GSE140860

ID:: 200140860

Select item 2000622378.

Secondary proteasome inhibitor carfilzomib resistant myeloma cell lines

(Submitter supplied) Modulation of the activity of the ubiquitin-proteasome pathway with the proteasome inhibitor (PI) is an established component of therapy for plasma cell disorders. However, resistance emerges and the mechanism is incompletely understood. We generated carfilzomib-resistant (CR) myeloma cell lines by exposing drug-naive ANBL-6, KAS-6/1, U266, and OPM-2 cells to increasing concentrations of carfilzomib and then performed gene expression profiling (GEP) to identify prominent changes compared to their vehicle-treated counterparts, followed by exploration of the mechanism(s) of proteasome inhibitor resistance.

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL10558
8 Samples

Download data: IDAT, TXT

Series

Accession:: GSE62237

ID:: 200062237

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2001533819.

Chromatin accessibility and gene expression maps of Plasma Cells and Myeloma Plasma Cells

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Homo sapiens

Type:: Genome binding/occupancy profiling by high throughput sequencing; Expression profiling by high throughput sequencing

Platform:: GPL20301
77 Samples

Download data: BED, BW

Series

Accession:: GSE153381

ID:: 200153381

PubMed Full text in PMC Similar studies

Select item 20015338010.

Chromatin accessibility and gene expression maps of Plasma Cells and Myeloma Plasma Cells [RNA-seq]

(Submitter supplied) We report the application of paired Assay for Transposase-Accessible Chromatin (ATAC-seq) and RNA-seq data to profile the regulatory landscape and expression of 5 primary Plasma Cell (PC), 28 Multiple Myeloma (MM) PC as well as 5 cell lines samples. Findings discriminated MM and MM subgroup-specific changes such as the exclusive overexpression of CCND1 and CCND2 oncogenes. DNA accessibility changes were correlated to gene expression in a topologically constrained manner to elucidate novel enhancer - promoter interactions, genes and pathways critical for myeloma biology and developmentally activated or de novo formed enhancers. more...

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL20301
38 Samples

Download data: TSV

Series

Accession:: GSE153380

ID:: 200153380

PubMed Full text in PMC Similar studies Analyze with GEO2R SRA Run Selector

Select item 20015337911.

Chromatin accessibility and gene expression maps of Plasma Cells and Myeloma Plasma Cells [ATAC-seq]

Organism:: Homo sapiens

Type:: Genome binding/occupancy profiling by high throughput sequencing

Platform:: GPL20301
39 Samples

Download data: BED, BW, TSV

Series

Accession:: GSE153379

ID:: 200153379

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 20004387812.

Control of Autophagic Cell Death by Caspase-10 in Multiple Myeloma

(Submitter supplied) We performed a loss-of-function, RNA interference screen to define new therapeutic targets in multiple myeloma, a genetically diverse plasma cell malignancy. Unexpectedly, we discovered that all myeloma lines require caspase-10 for survival, irrespective of their genetic abnormalities. The transcription factor IRF4 induces both caspase-10 and its associated protein cFLIPL in myeloma, generating a protease that does not induce apoptosis but rather blocks an autophagy-dependent cell death pathway. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL3278
40 Samples

Download data: GPR

Series

Accession:: GSE43878

ID:: 200043878

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20004860213.

Miz1 is required to maintain autophagic flux

(Submitter supplied) Miz1 is a zinc finger protein that regulates expression of cell cycle inhibitors as part of a complex with Myc. Cell cycle-independent functions of Miz1 are poorly understood. Here, we use a Nestin-Cre transgene to delete an essential domain of Miz1 in the central nervous system (Miz1ΔPOZNes). Miz1ΔPOZNes mice display cerebellar neurodegeneration characterized by the progressive loss of Purkinje cells. more...

Organism:: Homo sapiens; Mus musculus

Type:: Genome binding/occupancy profiling by high throughput sequencing

Platforms:: GPL10999 GPL11002
4 Samples

Download data: BED

Series

Accession:: GSE48602

ID:: 200048602

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 20009935814.

The role of FAM46C in myeloma cells

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing; Expression profiling by array

Platforms:: GPL11154 GPL17586
11 Samples

Download data: CEL, CHP

Series

Accession:: GSE99358

ID:: 200099358

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20009935715.

The role of FAM46C in myeloma cells [array]

(Submitter supplied) FAM46C is one of the most recurrently mutated genes in multiple myeloma (MM), however its role in disease pathogenesis is not determined. Here we demonstrate that wild type (WT) FAM46C overexpression induces substantial cytotoxicity in MM cells. In contrast, FAM46C mutations found in MM patients abrogate this cytotoxicity indicating a MM survival advantage conferred by the FAM46C mutant phenotype. WT FAM46C overexpression downregulated IRF4, CEBPB, MYC and upregulated immunoglobulin (Ig) light chain and HSPA5/BIP. more...